Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0K4CD
|
||||
Former ID |
DIB012746
|
||||
Drug Name |
ASP-8477
|
||||
Indication | Neuropathic pain [ICD9: 356.0, 356.8; ICD10:G64, G90.0] | Phase 2 | [1] | ||
Company |
Astellas Pharma Inc
|
||||
Target and Pathway | |||||
Target(s) | VEGF receptor | Target Info | Modulator | [1] | |
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
Cytokine-cytokine receptor interaction | |||||
HIF-1 signaling pathway | |||||
Endocytosis | |||||
PI3K-Akt signaling pathway | |||||
Focal adhesion | |||||
Transcriptional misregulation in cancer | |||||
Rheumatoid arthritis | |||||
References | |||||
REF 1 | ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.